AG
ABOS icon

Algert Global’s Acumen Pharmaceuticals ABOS Stock Holding History

Algert Global’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,410
Closed -$50K – 1483
2024
Q1 		$50K Buy
+12,410
New +$46.8K ﹤0.01% 1035

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Algert Global's ABOS Position: Q2 2024 in Review

Algert Global sold out of Acumen Pharmaceuticals (ABOS) in Q2 2024, closing a stake of 12,410 shares — an estimated $50K sold.

Algert Global first reported a position in ABOS in Q1 2024 and held it in 1 quarter. The position peaked at $50K in Q1 2024. 81 funds tracked by Wall St. Rank hold ABOS as of Q2 2024.

  • Algert Global reported no remaining Acumen Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Algert Global sold 12,410 Acumen Pharmaceuticals shares in Q2 2024, an estimated $50K.
  • Algert Global first reported a position in Acumen Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Algert Global's Acumen Pharmaceuticals position peaked at $50K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2024.

Based on Algert Global's 13F filing for Q2 2024, filed 15 Aug 2024.